Phagenesis appoints chairman and ceo

Will lead the development of treatments for stroke victims

Phagenesis, a UK leader in technology for the treatment of stroke patients, has appointed Henry Hyde-Thomson as chairman and Daniel Green as chief executive. They will lead the University of Manchester spin out in the development of a new class of treatments for stroke victims suffering from dysphagia, a condition that prevents or impairs the safe swallowing of food and drink.

Phagenesis’ technology is a device that delivers electrical pulses to the throat region that can ‘awaken’ the brain to help restore swallowing function. At least 50% of stroke victims have impaired swallowing. Apart from a severe reduction in quality of life, dysphagia often leads to the inhalation of liquids and the development of life-threatening pneumonia.

Green was formerly chief executive of Repregen, an Imperial College spinout. Before that, he was a venture capital investor at HBM Partners in Zurich, Switzerland, Dresdner Kleinwort and MVM, in London, UK.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development

Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation

New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Manufacturing

Cutting-edge wiped film evaporator installation – non-tobacco nicotine products

Successful system installation for a UK research and development facility developing and commercialising non-tobacco nicotine products using industry-leading evaporation equipment
Manufacturing

Why integrated outsourcing wins in modern drug development

Aligning drug substance and drug product development within a single outsourcing model accelerates timelines, sharpens CMC decisions and reduces risk by enabling parallel workstreams and shared governance
Manufacturing

Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics

All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing
Subscribe now